IP Library Granted Patent US 9,546,194
Granted Patent B2
US 9,546,194 · App. 14/394,789 · Granted Jan 17, 2017

Aminosteroids for the treatment of a PTP1B associated disease

Inventors: Michael McLane (Lansdale, PA); Inez Ruiz-White (Mount Laurel, NJ); W. Lee Maloy (Lansdale, PA); Henry R. Wolfe (Glenmoore, PA)
Assignee: Ohr Pharmaceutical, Inc.
C07J41/0005C07J41/005C07J41/0055C07J43/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,546,194
App. No.
14/394,789
Granted
Jan 17, 2017
Kind
B2
Abstract

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Claims (10)

1. A compound or pharmaceutically acceptable salt thereof selected from the group consisting of:

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable diluent or carrier.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is

4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is

5. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable diluent or carrier.

6. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable diluent or carrier.

7. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is

8. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is

9. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable diluent or carrier.

10. A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable diluent or carrier.

Assignments (4)
MERGER Recorded May 24, 2021
From: OHR PHARMACEUTICAL, INC.
To: NEUBASE THERAPEUTICS INC.
Reel/Frame 056328/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: NEUBASE THERAPEUTICS INC.
To: DEPYMED INC.
Reel/Frame 056328/0189 →
CHANGE OF ADDRESS Recorded Apr 27, 2015
From: OHR PHARMACEUTICAL, INC.
To: OHR PHARMACEUTICAL, INC.
Reel/Frame 035506/0727 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: MCLANE, MICHAEL; RUIZ-WHITE, INEZ; MALOY, W. LEE; WOLFE, HENRY R.
To: OHR PHARMACEUTICAL, INC.
Reel/Frame 035426/0531 →
Continuity (2)
Provisional Application 61636252 · Apr 20, 2012
Related Publication 20150099727A1 · Apr 9, 2015